Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

Beyond neurology, we have determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. We additionally intend to leverage our proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations.


Pepinemab for Neurology

Pepinemab for Immuno-Oncology